James Michelle L, Fulton Roger R, Vercoullie Johnny, Henderson David J, Garreau Lucette, Chalon Sylvie, Dolle Frederic, Costa Barbara, Guilloteau Denis, Kassiou Michael
Department of Pharmacology, University of Sydney, Sydney, New South Wales, Australia.
J Nucl Med. 2008 May;49(5):814-22. doi: 10.2967/jnumed.107.046151. Epub 2008 Apr 15.
The translocator protein (18 kDa) (TSPO), formerly known as the peripheral benzodiazepine receptor, is dramatically upregulated under pathologic conditions. Activated microglia are the main cell type expressing the TSPO at sites of central nervous system pathology. Radioligands for the TSPO can therefore measure active disease in the brain. This article details the synthesis, radiofluorination, and pharmacologic evaluation of a new TSPO-specific pyrazolopyrimidine, DPA-714.
The affinity of DPA-714 for the TSPO was measured in rat kidney membranes with (3)H-PK11195. The in vitro functional activity of DPA-714 was measured in a steroidogenic assay in which the ability of DPA-714 to increase pregnenolone synthesis was measured with rat C6 glioma cells. The radiofluorination of DPA-714 was achieved by nucleophilic (18)F-fluoride displacement of the tosylate precursor. (18)F-DPA-714 was assessed in rats harboring unilateral quinolinic acid (QA) lesions. In addition, pretreatment experiments were performed with PK11195 (5 mg/kg), DPA-714 (1 mg/kg), and DPA-713 (1 mg/kg). The in vivo binding and biodistribution of (18)F-DPA-714 were determined in a baboon with PET. Experiments involving presaturation with PK11195 (1.5 mg/kg) and displacement with DPA-714 (1 mg/kg) were conducted to evaluate the specificity of radioligand binding.
In vitro binding studies revealed that DPA-714 displayed a high affinity for the TSPO (dissociation constant, 7.0 nM). DPA-714 stimulated pregnenolone synthesis at levels 80% above the baseline. (18)F-DPA-714 was prepared at a 16% radiochemical yield and a specific activity of 270 GBq/mumol. In rats harboring unilateral QA lesions, an 8-fold-higher level of uptake of (18)F-DPA-714 was observed in the ipsilateral striatum than in the contralateral striatum. Uptake in the ipsilateral striatum was shown to be selective because it was inhibited to the level in the contralateral striatum in the presence of PK11195, nonlabeled DPA-714, or DPA-713. PET studies demonstrated rapid penetration and good retention of (18)F-DPA-714 in the baboon brain. Pretreatment with PK11195 effectively inhibited the uptake of (18)F-DPA-714 in the whole brain, indicating its selective binding to the TSPO. The injection of nonlabeled DPA-714 20 min after the injection of (18)F-DPA-714 resulted in radioligand washout, demonstrating the reversibility of (18)F-DPA-714 binding.
(18)F-DPA-714 is a specific radioligand for the TSPO, displaying promising in vivo properties and thus warranting further investigation.
转位蛋白(18 kDa)(TSPO),以前称为外周苯二氮䓬受体,在病理条件下会显著上调。活化的小胶质细胞是中枢神经系统病理部位表达TSPO的主要细胞类型。因此,TSPO的放射性配体可用于测量脑部的活动性疾病。本文详细介绍了一种新型TSPO特异性吡唑并嘧啶DPA - 714的合成、放射性氟化及药理学评估。
用(3)H - PK11195在大鼠肾膜中测量DPA - 714对TSPO的亲和力。在类固醇生成试验中测量DPA - 714的体外功能活性,该试验通过大鼠C6胶质瘤细胞测量DPA - 714增加孕烯醇酮合成的能力。DPA - 714的放射性氟化通过对甲苯磺酸盐前体进行亲核(18)F - 氟化物取代来实现。在患有单侧喹啉酸(QA)损伤的大鼠中评估(18)F - DPA - 714。此外,用PK11195(5 mg/kg)、DPA - 714(1 mg/kg)和DPA - 713(1 mg/kg)进行预处理实验。用正电子发射断层扫描(PET)在一只狒狒中测定(18)F - DPA - 714的体内结合和生物分布。进行了用PK11195(1.5 mg/kg)预饱和并用DPA - 714(1 mg/kg)置换的实验,以评估放射性配体结合的特异性。
体外结合研究表明,DPA - 714对TSPO具有高亲和力(解离常数为7.0 nM)。DPA - 714刺激孕烯醇酮合成的水平比基线高80%。(18)F - DPA - 714的制备放射化学产率为16%,比活度为270 GBq/μmol。在患有单侧QA损伤的大鼠中,观察到同侧纹状体中(18)F - DPA - 714的摄取水平比 contralateral 纹状体高8倍。同侧纹状体中的摄取显示是选择性的,因为在存在PK11195、未标记的DPA - 714或DPA - 713的情况下,其被抑制到 contralateral 纹状体中的水平。PET研究表明(18)F - DPA - 714在狒狒脑中快速渗透并具有良好的滞留性。用PK11195预处理有效抑制了(18)F - DPA - 714在全脑中的摄取,表明其与TSPO的选择性结合。在注射(18)F - DPA - 714后20分钟注射未标记的DPA - 714导致放射性配体洗脱,证明了(18)F - DPA - 714结合的可逆性。
(18)F - DPA - 714是TSPO的特异性放射性配体,具有有前景的体内特性,因此值得进一步研究。